Rezolute (Nasdaq:RZLT) - 주가, 뉴스 및 분석

RZLT 주식 개요

후기 단계의 희귀질환 회사인 레졸루트는 미국에서 고인슐린증으로 인한 저혈당증 환자의 치료 결과를 개선하는 데 주력하고 있습니다. 자세한 내용

RZLT 기본 분석
눈송이 점수
가치 평가	3/6
미래 성장	2/6
과거 실적	0/6
재무 상태	6/6
배당금	0/6

보상

공정 가치 추정치보다 낮은 97% 에서 거래

수익은 연간 69.21% 증가할 것으로 예상됩니다.

위험 분석

수익이 1백만 달러 미만인 경우 ( $0 )

현재 수익성이 없으며 향후 3년 동안 수익을 낼 것으로 예상되지 않습니다.

지난 1년 동안 주주가 희석되었습니다.

Rezolute, Inc. 경쟁사

AVITA Medical

NasdaqCM:RCEL

US$313.4m

Poseida Therapeutics

NasdaqGS:PSTX

US$269.0m

Mersana Therapeutics

NasdaqGS:MRSN

US$273.0m

iTeos Therapeutics

NasdaqGM:ITOS

US$300.7m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Rezolute
과거 주가
현재 주가	US$5.29
52주 최고치	US$6.19
52주 최저치	US$0.72
베타	1.19
11개월 변경	9.07%
3개월 변경 사항	21.89%
1년 변경 사항	605.24%
33년 변화	-2.04%
5년 변화	-29.65%
IPO 이후 변화	-99.20%

최근 뉴스 및 업데이트

Recent updates

We Think Rezolute (NASDAQ:RZLT) Needs To Drive Business Growth Carefully

May 22

Rezolute, Inc. (NASDAQ:RZLT) Shares Could Be 31% Above Their Intrinsic Value Estimate

Feb 13

Rezolute, Inc.'s (NASDAQ:RZLT) Intrinsic Value Is Potentially 65% Above Its Share Price

Sep 21

What Type Of Shareholders Make Up Rezolute, Inc.'s (NASDAQ:RZLT) Share Registry?

Jan 12

주주 수익률

	RZLT	US Biotechs	US 마켓
7D	-11.2%	-10.3%	-2.1%
1Y	605.2%	13.6%	29.6%

수익률 대 산업: RZLT 지난 1년 동안 13.6 %를 반환한 US Biotechs 산업을 초과했습니다.

수익률 대 시장: RZLT 지난 1년 동안 29.6 %를 반환한 US 시장을 초과했습니다.

가격 변동성

Is RZLT's price volatile compared to industry and market?
RZLT volatility
RZLT Average Weekly Movement	9.5%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.5%
10% least volatile stocks in US Market	3.1%

안정적인 주가: RZLT 는) 지난 3개월 동안 큰 가격 변동성이 없었습니다.

시간에 따른 변동성: RZLT 의 주간 변동성( 10% )은 지난 1년 동안 안정적인 모습을 보였습니다.

회사 소개

설립	직원	CEO	웹사이트
2010	18	Nevan Elam	www.rezolutebio.com

후기 단계 희귀질환 회사인 Rezolute, Inc.는 미국에서 고인슐린증으로 인한 저혈당증 환자의 치료 결과를 개선하는 데 주력하고 있습니다. 이 회사의 주요 제품 후보는 극희귀 소아 유전 질환인 선천성 고인슐린증 치료를 위한 임상 3상 시험 중인 인간 단일 클론 항체 에소데투그(ersodetug)입니다. 또한 만성 당뇨병성 황반부종 치료를 위해 임상 2상 중인 경구용 혈장 칼리크레인 억제제인 RZ402를 개발 중입니다.

Rezolute, Inc. 기본 사항 요약

Rezolute 의 수익과 매출은 시가총액과 어떻게 비교하나요?
RZLT 기본 통계
시가총액	US$295.86m
수익(TTM)	-US$69.31m
수익(TTM)	n/a

0.0x

P/S 비율

-4.3x

P/E 비율

RZLT 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
RZLT 손익 계산서(TTM)
수익	US$0
수익 비용	US$0
총 이익	US$0
기타 비용	US$69.31m
수익	-US$69.31m

최근 보고된 수익

Sep 30, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-1.24
총 마진	0.00%
순이익 마진	0.00%
부채/자본 비율	0%

RZLT 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

RZLT 주식 개요

보상

위험 분석

Rezolute, Inc. 경쟁사

NasdaqCM:RCEL

US$313.4m

NasdaqGS:PSTX

US$269.0m

NasdaqGS:MRSN

US$273.0m

NasdaqGM:ITOS

US$300.7m

가격 내역 및 성능

최근 뉴스 및 업데이트

Price target increased by 7.5% to US$12.78

Rezolute, Inc., Annual General Meeting, Dec 05, 2024

Price target increased by 7.2% to US$12.75

Consensus EPS estimates upgraded to US$0.98 loss

Insufficient new directors

Price target increased by 8.1% to US$11.89

Recent updates

Price target increased by 7.5% to US$12.78

Rezolute, Inc., Annual General Meeting, Dec 05, 2024

Price target increased by 7.2% to US$12.75

Consensus EPS estimates upgraded to US$0.98 loss

Insufficient new directors

Price target increased by 8.1% to US$11.89

New major risk - Shareholder dilution

Rezolute, Inc. Announces FDA Clearance of IND Application for Phase 3 Registrational Study of RZ358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

Rezolute, Inc. announced that it expects to receive $6 million in funding

Rezolute, Inc. has completed a Follow-on Equity Offering in the amount of $59.99625 million.

New major risk - Share price stability

Price target increased by 9.4% to US$10.57

Rezolute, Inc. Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME)

We Think Rezolute (NASDAQ:RZLT) Needs To Drive Business Growth Carefully

Rezolute, Inc., Annual General Meeting, May 16, 2024

Director recently bought US$70k worth of stock

Rezolute, Inc. Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)

Chief Financial Officer recently bought US$67k worth of stock

Price target increased by 9.0% to US$8.50

Rezolute, Inc. (NASDAQ:RZLT) Shares Could Be 31% Above Their Intrinsic Value Estimate

Now 29% overvalued after recent price rise

Rezolute, Inc. Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism

Rezolute, Inc. Appoints Daron Evans as Chief Financial Officer

Rezolute, Inc. Announces Completion of Enrollment in its RZ402 Phase 2 Study in Diabetic Macular Edema

Rezolute Receives a Written Notice from the Listing Qualifications Department of Nasdaq Stock Market

New minor risk - Shareholder dilution

New minor risk - Share price stability

Rezolute Announces Further Evidence of RZ358’s Efficacy in Tumor-Mediated Hyperinsulinism

Rezolute, Inc.'s (NASDAQ:RZLT) Intrinsic Value Is Potentially 65% Above Its Share Price

Here's Why We're Watching Rezolute's (NASDAQ:RZLT) Cash Burn Situation

New major risk - Revenue and earnings growth

Price target decreased by 30% to US$7.80

Rezolute, Inc. Provides an Update on Its Clinical Development Plans for RZ358

Rezolute, Inc. to Report Q3, 2023 Results on May 11, 2023

Price target decreased by 7.9% to US$11.60

We Think Rezolute (NASDAQ:RZLT) Can Afford To Drive Business Growth

Rezolute, Inc. Announces Initiation of A Phase 2 Study of Rz402 in Patients with Diabetic Macular Edema

High number of new and inexperienced directors

Price target decreased to US$12.60

Rezolute GAAP EPS of -$0.37

Rezolute, Inc. Promotes Brian Roberts to Chief Medical Officer

Rezolute, Inc. has completed a Follow-on Equity Offering in the amount of $50 million.

Price target decreased to US$19.20

Rezolute, Inc. has completed a Follow-on Equity Offering in the amount of $117.587085 million.

Rezolute, Inc. Announces Positive Data from its Phase 2b (RIZE) Study of RZ358 in Patients with Congenital Hyperinsulinism

Rezolute, Inc., Annual General Meeting, Jun 30, 2022

High number of new and inexperienced directors

Rezolute, Inc Announces Positive Study Results for RZ402, an oral PKI being developed for DME

Rezolute, Inc. Presents Results from Two-Week Natural History Study in Congenital Hyperinsulinism Patients on Standard of Care Therapies At ESPE 2021

Rezolute, Inc. Announces Initiation of Dosing in the Second Cohort of its Phase 2b Trial of RZ358 for Congenital Hyperinsulinism

Rezolute, Inc. Announces Initiation of Multiple-Ascending Dose Study of RZ402, Rezolute’s Oral PKI for Treatment of DME

Price target decreased to US$26.50

High number of new and inexperienced directors

Price target decreased to US$27.00

We're Keeping An Eye On Rezolute's (NASDAQ:RZLT) Cash Burn Rate

Rezolute, Inc. Announces Positive RZ402 Study Results Demonstrating Potential for Once Daily Dosing of an Oral Plasma Kallikrein Inhibitor for Diabetic Macular Edema

Rezolute shares rise on positive topline results from RZ402 eye disease trial

Rezolute, Inc. Announces Board Appointments

New 90-day low: US$11.98